# About Sermorelin Medicine: An Independent Editorial Digest

> About Sermorelin Medicine — an independent editorial project that publishes cited, plain-English summaries of the peer-reviewed research on sermorelin (GHRH(1-29)). Not a clinic, not a vendor.

An independent editorial board reading the sermorelin literature — what it is, what it is not, and the line we hold.

## What this site is

Sermorelin Medicine is an independent editorial project that publishes summaries of the peer-reviewed research literature on **sermorelin** (GHRH(1-29)). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — the mechanism, the GH-axis and cognition trials, and the honest limits of the adult evidence, each finding cited to its source.

## What the name means

The word "medicine" in the name is editorial framing — a position this publisher occupies relative to the literature, not a claim about services this site provides. Sermorelin's history makes the word especially worth handling carefully: sermorelin acetate was once an FDA-approved pediatric medicine (NDA 020443), was withdrawn from the US market in 2008 for commercial reasons, and is now prepared by compounding pharmacies. So sermorelin genuinely was a medicine, and is studied as a research compound today.

That history is exactly why we are explicit about a distinction many sources blur: research-grade sermorelin described here is not presented as a current medicine to take. "Formerly FDA-approved, now compounded" is the accurate frame, and we keep the approved-pediatric history, the adult research, and the compounded present clearly separated rather than collapsed into a single marketing pitch.

## How we read the literature

Our method is simple and consistent. Every quantitative claim — a dose, a percentage, a half-life, a P-value — is tied to a specific published study and listed on the references page. We lead with what the trials established and mark the gaps where the evidence runs thin, including the limited long-term adult data and the theoretical GH/IGF-1 caution. Where a result comes from a related analog such as tesamorelin rather than native sermorelin, we say so. We avoid product, vendor, and brand framing entirely. The aim is a sober reading board: the published record on sermorelin, organized and cited, with the honest caveats kept visible.

---

A constructivist reading board for the sermorelin record — every GHRH(1-29) figure logged to its study and the empty long-term adult-evidence members left openly unfilled; sermorelin was a medicine, is read here as research, and nothing on this board is dispensed, prescribed, or sold.